Full-Time

Manufacturing Specialist

Updated on 9/3/2026

Evonik

Evonik

10,001+ employees

Global specialty chemicals manufacturer and supplier

No salary listed

Birmingham, AL, USA

In Person

Bachelor's, Associate's

Category
Biology & Biotech (1)

Get referred to Evonik

See people who can refer or advise you

Requirements
  • A Bachelor of Arts or Bachelor of Science degree in a STEM subject, or a combination of education and relevant experience.
  • An Associate of Arts or Associate of Science degree in a related subject and 2–4 or more years of relevant experience.
  • A high school degree in a related subject and 4 or more years of relevant experience.
  • Strong understanding of current Good Manufacturing Practices, Good Documentation Practices, and regulatory standards including the Food and Drug Administration and European Medicines Agency requirements.
  • Experience with cleanroom operations and batch execution.
  • Proven ability to support or lead training programs for manufacturing staff.
  • Familiarity with validation protocols and regulatory expectations.
  • Ability to communicate and collaborate cross-functionally.
  • Ability to work in a regulated environment with changing priorities.
  • Flexibility to train on the day shift and transition to the assigned shift schedule as needed.
Responsibilities
  • Execute current Good Manufacturing Practices batch manufacturing processes in cleanroom environments.
  • Ensure regulatory compliance with the Food and Drug Administration, European Medicines Agency, International Pharmaceutical Excipients Council, and International Organization for Standardization requirements within manufacturing operations.
  • Train frontline personnel and support the development and maintenance of training materials and curricula.
  • Lead safety, environmental compliance, and housekeeping initiatives in manufacturing areas.
  • Collaborate cross-functionally with internal departments and management on production readiness and process transfer activities.
  • Support contract manufacturing organization readiness and participate in client interactions, including site tours and meetings.
  • Monitor and improve Good Manufacturing Practice documentation practices, training effectiveness, deviation root cause analysis, and release processes.
  • Ensure adherence to Good Documentation Practices and support maintenance shutdowns as needed.
  • Execute installation, operational, and qualification and process performance qualification validation activities with minimal supervision.
  • Identify and implement continuous improvement opportunities in manufacturing systems and processes.

Evonik is a global specialty chemicals company that makes high-value ingredients used in everyday products, such as cars, footwear, and animal feed. Its products are designed to enhance performance by providing tailored chemical solutions across multiple industries and applications. Evonik operates in more than 100 countries, producing specialty chemicals through advanced formulations and manufacturing processes that meet specific customer needs. The company differentiates itself by its focused strategy on high-margin specialty chemicals after restructuring, its large, multinational manufacturing footprint, and ongoing efficiency-improvement efforts that paused major acquisitions through 2027 to prioritize internal transformation. The goal is to strengthen its leadership in specialty chemicals and sustain profitable growth by delivering specialized ingredients and performance materials while improving operational efficiency.

Company Size

10,001+

Company Stage

IPO

Headquarters

Essen, Germany

Founded

2007

Get referred to Evonik

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • August 4, 2026 Q2 adjusted EBITDA rose 24% to €630 million, a four-year high.
  • Evonik raised 2026 EBITDA guidance to €2.0-€2.2 billion after stronger volumes and pricing.
  • Vancouver and Lafayette investments, announced August 27 and July 8, 2026, expand pharma capacity.

What critics are saying

  • Reuters on June 18, 2026 said Evonik will cut 3,200 jobs through 2029.
  • Evonik plans to discontinue polyester in 2027 after years of losses and failed buyer talks.
  • Oxeno divestment and weak European margins expose Evonik to permanent portfolio shrinkage by 2027.

What makes Evonik unique

  • Evonik’s 2026 portfolio shift targets specialty chemicals, not commodity volumes, unlike BASF or Solvay.
  • Its Tippecanoe and Vancouver pharma CDMO assets anchor high-margin drug delivery and API services.
  • Evonik’s AEM hydrogen membrane and Rocket recycling modules create proprietary process-technology adjacency.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Disability Insurance

Life Insurance

Parental Leave

Tuition Reimbursement

401(k) Retirement Plan

Health Savings Account/Flexible Spending Account

Paid Vacation

Flexible Work Hours

Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

11%
PR Newswire
Aug 27th, 2026
Evonik invests $109.5M in new lipid drug delivery facility in Vancouver

Evonik is investing over C$150 million (€93 million) in a new GMP manufacturing facility for lipid-based drug delivery in Vancouver, Canada. The Canadian federal government's Strategic Response Fund is supporting the project with up to C$68 million (around €42 million). The facility will more than triple Evonik's current production capacity for advanced pharmaceutical products, including vaccines and therapeutics. Drug product production is planned to begin at the end of 2029. The expansion builds on Evonik Vancouver Laboratories' expertise in lipid-based drug delivery since the 1990s. The site provides CDMO services for advanced LNP and liposomal delivery systems, from formulation research through GMP clinical trial manufacturing. The LNP market is projected to reach $2.7 billion by 2034, driven by growing demand for nucleic acid therapeutics.

Yahoo Finance
Aug 13th, 2026
Evonik's 24% Q2 EBITDA surge drives polymeric surfactants market to projected $17.8B by 2035

Evonik reported a 24% surge in Q2 EBITDA, while the global polymeric surfactants market is projected to reach $17.8 billion by 2035, according to a new report from ResearchAndMarkets.com. The market was valued at $10.5 billion in 2025 and is expected to grow at a 5.4% CAGR through 2035. Growth is driven by the transition towards water-based and low-VOC systems in coatings, paints, personal care, and industrial applications. Block copolymers held a 42.2% market share in 2025, making them the leading product category. Their dominance stems from precise molecular structure control and versatility across multiple applications including coatings, pharmaceuticals, agriculture, and personal care. The personal care and cosmetics industry represents a key growth area, fuelled by consumer demand for premium products offering improved texture and stability. Manufacturers are increasingly incorporating polymeric surfactants into product development as regulatory requirements and sustainability objectives evolve.

PR Newswire
Jul 8th, 2026
Evonik invests $100M to upgrade Indiana drug substance manufacturing facility

Evonik is investing $100 million over five years to modernise its drug substance manufacturing facility in Lafayette, Indiana. The investment will upgrade equipment including 100 m³ reactors, enhance automation, and improve efficiency at the site. The German chemicals company aims to meet growing demand for US-based contract development and manufacturing organisation services. The Tippecanoe facility is Evonik's second-largest US site and one of the world's largest active pharmaceutical ingredient facilities. The site features 170 m³ of high-potency API capacity, 860 m³ of reactor capacity for general APIs, and 2,500 m³ for large-scale fermentation. Evonik acquired the facility from Eli Lilly in 2010. The modernisation supports production of increasingly complex molecules for cancer, metabolic, and cardiovascular disease treatments whilst reducing greenhouse gas emissions.

AktienSensor
Jun 10th, 2026
Evonik shareholder raises $424M via convertible debt to fund R&D and bolster capital structure

Evonik Industries' principal shareholder, RAG-Stiftung, has issued €375 million in convertible debt maturing in December 2031. The note carries a 1.45% coupon and a conversion price of €19.46 per share, representing a 27% premium over the reference price at issuance. The transaction is part of RAG-Stiftung's long-term capital-raising framework, bringing its total outstanding convertible debt to approximately €1.4 billion. The low coupon reflects disciplined interest expense management in the specialty-chemicals sector. If converted, the debt would retire and dilute the foundation's equity stake by less than 1%. The proceeds will support research and development spending and provide a buffer against commodity price volatility. The German specialty-chemicals company faces competition from BASF, Lanxess and Solvay in high-performance polymers and advanced additives.

Yahoo Finance
Jun 10th, 2026
Evonik launches membrane to cut green hydrogen costs by 25%

German chemicals group Evonik has developed a membrane for electricity-based hydrogen production that could significantly reduce costs. Commercial manufacturing of the Anion Exchange Membrane (AEM) electrolysis system has begun at a pilot plant in Germany's Ruhr region. The technology uses fewer precious metals than traditional methods and allows hydrogen to be produced under pressure, eliminating additional compression steps. Specialist studies suggest the system could reduce investment costs by at least 25%. Green hydrogen currently costs two to four times more than grey hydrogen produced from natural gas. Evonik is targeting large-scale application in China, where it has established a technology centre in Shanghai to test the membranes under industrial conditions with local partners. The company expects strong demand growth for green hydrogen as industries transition to carbon neutrality.